Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti‐CD28 Domain Antibody Antagonist in Healthy Subjects

We report pharmacokinetics, pharmacodynamics, and safety of a novel anti‐CD28 domain antibody antagonist (lulizumab pegol) in healthy subjects following single‐ or multiple‐dose administration. A minimal anticipated biological effect level approach was used to select a 0.01 mg starting dose for a si...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Rong, Honczarenko, Marek, Zhang, Sean, Fleener, Catherine, Mora, Johanna, Lee, Sun Ku, Wang, Reena, Liu, Xiaoni, Shevell, Diane E., Yang, Zheng, Wang, Haiqing, Murthy, Bindu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Pharmacokinetics/Pharmacodynamics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697635/
https://www.ncbi.nlm.nih.gov/pubmed/27402064
http://dx.doi.org/10.1002/jcph.791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697635/
https://www.ncbi.nlm.nih.gov/pubmed/27402064
http://dx.doi.org/10.1002/jcph.791

Ejemplares similares